Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 9/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770523 | 0.94 | FFAR1 (0.36) | APPFFAR1MAOBMAOA | |
| SCHEMBL14770524 | 0.91 | APP (0.40) | APPFFAR1MAOBMAOAMMP1 | |
| SCHEMBL12066059 | 0.85 | MAOB (0.39) | APPFFAR1MAOBMAOAMMP1 | |
| SCHEMBL14770518 | 0.85 | NPC1 (0.40) | APPFFAR1MAOB | |
| SCHEMBL14770631 | 0.84 | GSK3A (0.36) | — | |
| SCHEMBL12065636 | 0.82 | MLKL (0.42) | FFAR1MAOBMAOA | |
| SCHEMBL14770522 | 0.81 | NPC1 (0.37) | APPFFAR1MAOBMAOA | |
| SCHEMBL14770571 | 0.79 | KMT2A (0.46) | APPFFAR1MAOBMAOA | |
| SCHEMBL12066068 | 0.78 | MAOB (0.40) | APPFFAR1MAOBMAOA | |
| SCHEMBL14763411 | 0.77 | FFAR1 (0.39) | APPFFAR1MAOBMAOAMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | APP 2799/4885FFAR1 1112/4885MAOB 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.